Zuberbier T, Asero R, Bindslev-Jensen C et al (2009) EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy 64(10):1427–1443

Article  CAS  PubMed  Google Scholar 

Zuberbier T, Aberer W, Asero R et al (2014) The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7):868–887

Article  CAS  PubMed  Google Scholar 

Zuberbier T, Aberer W, Asero R et al (2018) The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73(7):1393–1414

Article  CAS  PubMed  Google Scholar 

Bergstrom KG (2013) Chronic urticaria: omalizumab and review of therapeutic options. J Drugs Dermatol 12(6):715–716

PubMed  Google Scholar 

Staubach P, Metz M, Chapman-Rothe N et al (2016) Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 71(8):1135–1144

Article  CAS  PubMed  Google Scholar 

Saini SS, Bindslev-Jensen C, Maurer M et al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135(1):67–75

Article  PubMed  Google Scholar 

US FDA (2014) XOLAIR® (omalizumab) for injection, for subcutaneous use Initial U.S. Approval: 2003. Food and Drug Administration Web. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5211lbl.pdf. Accessed 18 Mar 2024

Kaplan A, Ledford D, Ashby M et al (2013) Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101–109

Article  CAS  PubMed  Google Scholar 

Hide M, Park HS, Igarashi A et al (2017) Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci 87(1):70–78

Article  CAS  PubMed  Google Scholar 

Yuan W, Hu S, Li M et al (2022) Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Dermatol Ther 35(4):e15303

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metz M, Staubach P, Bauer A et al (2017) Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics 7(5):1266–1276

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nettis E, Cegolon L, Di Leo E et al (2018) Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol 121(4):474–478

Article  CAS  PubMed  Google Scholar 

Muntyanu A, Ouchene L, Ben-Shoshan M, Netchiporouk E (2020) Ligelizumab is superior to omalizumab for chronic spontaneous urticaria. J Cutan Med Surg 24(2):201–202

Article  CAS  PubMed  Google Scholar 

Arm JP, Bottoli I, Skerjanec A et al (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44(11):1371–1385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer M, Giménez-Arnau AM, Sussman G et al (2019) Ligelizumab for chronic spontaneous urticaria. N Engl J Med 381(14):1321–1332

Article  CAS  PubMed  Google Scholar 

Maurer M, Ensina LF, Gimenez-Arnau AM et al (2023) Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. https://doi.org/10.1016/S0140-6736(23)01684-7

Article  PubMed  Google Scholar 

Upreti VV, Venkatakrishnan K (2019) Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence. Clin Pharmacol Ther 106(5):981–992

Article  PubMed  Google Scholar 

Chan P, Peskov K, Song X (2022) Applications of model-based meta-analysis in drug development. Pharm Res 39(8):1761–1777

Article  CAS  PubMed  PubMed Central  Google Scholar 

Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M (2008) How to assess disease activity in patients with chronic urticaria? Allergy 63(6):777–780

Article  PubMed  Google Scholar 

Hawro T, Ohanyan T, Schoepke N et al (2018) Comparison and interpretability of the available urticaria activity scores. Allergy 73(1):251–255

Article  CAS  PubMed  Google Scholar 

Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L (2017) Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev 18(12):1377–1385

Article  CAS  PubMed  Google Scholar 

Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37(2):179–201

Article  PubMed  Google Scholar 

Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graaf PH (2014) Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. CPT Pharmacometrics Syst Pharmacol 3(12):e153

PubMed  PubMed Central  Google Scholar 

European Medicines Agency (2014) Xolair (omalizumab) II-48 assessment report. European Medicines Agency. https://www.ema.europa.eu/en/documents/variation-report/xolair-h-c-606-ii-0048-epar-assessment-report-variation_en.pdf. Accessed 18 Mar 2024

Mathias SD, Crosby RD, Rosén KE, Zazzali JL (2015) The minimal important difference for measures of urticaria disease activity: updated findings. Allergy Asthma Proc 36(5):394–398

Article  CAS  PubMed  Google Scholar 

Maurer M, Rosén K, Hsieh HJ et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924–935

Article  CAS  PubMed  Google Scholar